ROLE OF INTRAVITREAL RANIBIZUMAB IN TREATING THE DIABETES MELLITUS TYPE-2 PATIENTS WITH SUBFOVEAL CHOROIDAL THICKNESS AND DIMINISHED VISUAL ACUITY

SIVA SANKAR PR; PRASAD YMS

doi:10.22159/ajpcr.2023v16i2.49513

Authors

SIVA SANKAR PR Department of Ophthalmology, Government Medical College, Anantapuramu, Andhra Pradesh, India.
PRASAD YMS Department of Ophthalmology, Government Medical College, Anantapuramu, Andhra Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2023v16i2.49513

Keywords:

Visual acuity, Choroid, Ligand preparation, Best-corrected visual acuity and Ranibizumab

Abstract

Objective: This study was conducted with the objective to measure the Subfoveal Choroid thickness and correlate it with the diminished visual acuity in patients with Diabetes Mellitus Type 2, who develop macular edema and to study the effect of Intravitreal injections of Ranibizumab during follow up.

Methods: A cross sectional, interventional study conducted in 52 patients with uncontrolled Diabetes Mellitus Type-2 with macular edema by measuring the Subfoveal Choroid thickness with the help of manual caliper function present in the Heidelberg Spectralis OCT program. Patients with SFCT less than 450 microns were included. The SFCT and the corresponding visual acuity were measured before and after Intravitreal Ranibizumab injections 1.25mg (0.05mL) at monthly intervals for 3 months and correlated with age, gender, and choroid thickness.

Results: Out of 52 patients there were 31 (59.61%) females and 21 (40.38%) males. 50% of the patients were aged between 50 and 60 years and 50% patients were aged between 60 and 70 years. The patients responding to the Intravitreal injections in terms of best-corrected visual acuity (BCVA) between the reinjection and post-injection were found to be statistically important (p=0.001). The subfoveal Choroidal thickness (SFCT) variations, before and after injections were found to be statistically significant at the end of 3 months (p<0.05).

Conclusions: Injection Ranibizumab was found to have a significant role in the reduction of average SFCT and in addition clear evidence of improved BCVA.

Downloads

Download data is not yet available.

References

Wright W, Eshaq R, Lee M, Kaur G, Harris NR. Retinal physiology and circulation: Effect of diabetes. Compr Physiol. 2020;10(3): 933-74.

Ong J, Zarnegar A, Corradetti G, Singh SR, Chhablani J. Advances in optical coherence tomography imaging technology and techniques for choroidal and retinal disorders. J Clin Med. 2022;11(17):5139.

Gupta C, Tan R, Mishra C, Khandelwal N, Raman R, Kim R, et al. Choroidal structural analysis in eyes with diabetic retinopathy and diabetic macular edema-a novel OCT based imaging biomarker. PLoS One. 2018;13:e0207435.

Chhablani J, Ruiz-Medrano J, editors. Choroidal Disorders. United States: Academic Press; 2017.

Huang X, Zhang P, Zou X, Xu Y, Zhu J, He J, et al. Thinner average choroidal thickness is a risk factor for the onset of diabetic retinopathy. Ophthalmic Res. 2020; 63(3):259-70.

Lupidi M, Cerquaglia A, Gujar R, Fruttini D, Piccolino FC, Fiore T, et al. Functional correlation between choroidal and retinal vascularity in low-grade diabetic retinopathy. Acta Diabetol. 2020;57:983-90.

Laíns I, Figueira J, Santos A, Baltar A, Costa M, Nunes S, et al. Choroidal thickness in diabetic retinopathy: The influence of antiangiogenic therapy. Retina. 2014;34(6):1199-207.

Yiu G, Manjunath V, Chiu S, Manjunath V, Chiu SJ, Farsiu S, et al. Effect of anti-vascular endothelial growth factor therapy on choroidal thickness in diabetic macular edema. Am J Ophthal Mol. 2014;158(4):745-51.

Lee HK, Lim JW, Shin MC. Comparison of choroidal thickness in patients with diabetes by spectral-domain optical coherence tomography. Korean J Ophthalmol. 2013 Dec;27(6):533-8.

Shiragami C, Shiraga F, Matsuo T, Matsuo T, Tsuchida Y, Ohtsu Risk factors for diabetic choroidopathy in patients with diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2002;240:436-42.

Lee H, Lim J, Shin M. Comparison of choroidal thickness in patients with diabetes by spectral-domain optical coherence tomography. Korean J Ophthalmol. 2013;27(6):433-9.

Rayess N, Rahimy E, Yig G, Bagheri N, Ho AC, Regillo CD, et al. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema. Am J Ophthalmol. 2015;159(1):85-91.

Kang H, Kwon H, Yi J, Lee CS, Lee SC. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. Am J Ophthalmol. 2014;157(5):1013-21.

Byeon S, Kwon Y, Oh H, Kim M, Kwon OW. Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema. J Ocul Pharmacol Ther. 2007;23(4):387-94.

Latalska M, Bartosińska J, Dresler S, Toro MD, Krasowska D, Rejdak R. Comparison of nailfold videocapillaroscopy with retinal and choroidal vascular parameters in patients with central serous chorioretinopathy. J Clin Med. 2023;12(14):4817.

Soman M, Ganekal S, Nair U, Nair K. Association of systemic comorbidity in diabetic serous macular detachment and comparison of various combination therapies in its management. Clin Ophthalmol. 2013;7:113-9.